The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Changes in prostate cancer incidence and treatment in USA
Open accessAbstract
We examined time trends and geographical variations in the detection and treatment of prostate cancer in USA, based on information from white men aged 50 to 79 who resided in areas covered by the Surveillance, Epidemiology, and End Results (SEER) program of the United States National Cancer Institute. Prostate-cancer incidence and treatment rates were determined for the 9 population-based cancer registries which participate in the SEER program. Prostate-cancer mortality rates were assessed from data compiled by the National Center for Health Statistics. Prostate cancer incidence rates increased by 6.4% per year between 1983 and 1989. The increase appeared to be due to detection of early-stage disease; there was no increase in the incidence rate of metastatic cancer. Incidence rates varied widely among the SEER program areas: in 1989 from 267.9 per 100,000 in Connecticut to 606.8 in Seattle. Radical prostatectomy rates more than tripled between 1983 and 1989 in the SEER areas as a whole. Among men aged 70-79, the rate of prostatectomy increased by nearly 35% per year. There was a five-fold variation among SEER areas in radical prostatectomy rates in 1989, with a low of 43.4 per 100,000 in Connecticut and a high of 224.4 in Seattle. Prostate cancer mortality rates did not increase during the period of study; there was little variation among areas in prostate-cancer mortality rates, and no apparent correlation between the incidence and mortality rates for an area. Increases in rates of prostate cancer incidence and prostate surgery have occurred in the United States without clear evidence that screening and prostectomy are effective in reducing mortality. Moreover, much of the growth in incidence and radical prostatectomy rates has occurred among older men, who appear least likely to benefit from early detection and surgery of occult prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy
Black, W. C., & Welch, H. G. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304293281706 · Cited by 547
Cited by
Dearnaley, D. P., Khoo, V. S., Norman, A. R., Meyer, L., Nahum, A., Tait, D., Yarnold, J., & Horwich, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05180-0 · Cited by 739
The Role of Increasing Detection in the Rising Incidence of Prostate Cancer
Potosky, A. L. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520310046028 · Cited by 674
Rethinking Screening for Breast Cancer and Prostate Cancer
Esserman, L. (2009) · JAMA · doi:10.1001/jama.2009.1498 · Cited by 516
Long-term Survival Among Men With Conservatively Treated Localized Prostate Cancer
Albertsen, P. C. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530080042039 · Cited by 464
on behalf of the Transatlantic Prostate Group, Cuzick, J., Berney, D. M., Fisher, G., Mesher, D., Møller, H., Reid, J. E., Perry, M., Park, J., Younus, A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.39 · Cited by 364
Metadata
- Authors
- Lu-Yao, G. L., & Greenberg, E. R.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1994-01
- Volume
- 343
- Issue
- 8892
- Pages
- 251-254
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1967463350
- Cited by
- 248
- References
- 1
- FWCI
- 39.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in prostate cancer incidence and treatment in USA. https://app.cochat.ai/papers/10.1016/s0140-6736(94)91109-6
- The paper
- Lu-Yao, G. L., & Greenberg, E. R. (1994). Changes in prostate cancer incidence and treatment in USA. The Lancet. https://doi.org/10.1016/s0140-6736(94)91109-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.